|
|
JLABS is part of Johnson & Johnson's external R&D engine and provides a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. The JLABS network encompasses a 40,000 square foot flagship facility in San Diego at Janssen's West Coast Research Center, dedicated space within Lab Central in Boston and QB3@953 in San Francisco, as well as a 30,000 square foot stand-alone facility in South San Francisco (opening 2015). The facilities feature core research labs hosting specialized capital equipment, shared administrative areas and individual bench, wet lab and office modules on a short term basis. Companies pay only for the space they need, with an option to quickly expand when they have the resources to do so. An operations team allows our companies to focus on the science and our business team provides access to education, experts and funding partners. JLABS is a no strings attached model and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen. JLABS services and amenities vary depending on location. JLABS is part of Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Paul Janssen was a world renowned Belgian physician and scientist. With 50,000 francs (less than US $2,000) from his father, Dr. Janssen founded a research laboratory and then went on to found Janssen Pharmaceutical, a company that discovered 80 new medicines. Paul Janssen's story embodies much of what we hope to achieve with JLABS. In that same entrepreneurial spirit, JLABS is the home for high-potential companies looking to transform healthcare with novel discoveries and limited upfront investment.
|
